JS105 + paclitaxel (albumin bound)

JS105 + paclitaxel (albumin bound) is an investigational combination regimen consisting of JS105, a potent and selective oral inhibitor of the alpha isoform of phosphoinositide 3-kinase (PI3Kα), and paclitaxel (albumin bound), a nanoparticle albumin-bound (nab) formulation of the taxane paclitaxel. Developed by Junshi Biosciences, JS105 is designed to target the PI3K/Akt/mTOR signaling pathway, which is frequently dysregulated in solid tumors, particularly those harboring PIK3CA mutations. Paclitaxel (albumin bound) acts as a microtubule-stabilizing agent that inhibits cell division by preventing the depolymerization of tubulin. This combination is currently being evaluated in Phase Ib/II clinical trials (e.g., NCT06208410) for patients with advanced solid tumors, including breast cancer, to assess safety, tolerability, and preliminary anti-tumor efficacy.

Other names

JS105 + nab-paclitaxelJS105 plus albumin-bound paclitaxelJS-105 plus albumin-bound paclitaxelJS 105 plus albumin-bound paclitaxelJS105 plus paclitaxel (albumin bound)